A New Adhesive-based Platform for Topical Skin Closure
Developed by Resivant MedicalCutiva™, the adhesive-based platform by Resivant Medical, promises to be the first truly disruptive replacement for staples and sutures. The goal is to offer a flowable adhesive with the flexibility and toughness of silicone and the strength of a cyanoacrylate super glue.
Today’s Skin Closure Problem
Sutures and staples are traditional closure products—in spite of their associated costs and often less than satisfactory outcomes.
Placing them adds to operating room time. A return visit for their removal can be painful, cost ineffective, and may add additional risk for new surgical site infection.
After removal, unsightly suture marks and scars are possible.
Tomorrow’s Skin Closure Solution:
Flexible, Strong, Durable and Fast
Resivant Medical is developing a unique, adhesive-based platform that promises to be an alternative to traditional sutures and staples: Cutiva™
With patents and patents pending, Cutiva™ uses a flowable adhesive that is strong, yet flexible. Unlike previously developed adhesives, Resivant’s goal is to offer a topical skin closure platform that will bend, stretch and remain in place during the healing process.
The Cutiva™ platform is expected to encompass adhesives and closure systems with a view toward treating a range of incision lengths.
Cutiva™ is not FDA cleared for human use at this time.
The Goal: Cost Savings and Improved Outcomes
Healthcare costs reduced by minimizing the time associated with performing traditional skin closures and eliminating follow up visits for suture removal
Improved outcomes through Cutiva’s™ unique characteristics; pre-design experiments show its gradual disappearance and a near seamless scar after application
Setting a new standard for how incisions are closed across multiple surgical specialties and procedures
The Cutiva™ adhesive platform is not FDA cleared for human use at this time.